The FDA has accepted Pharming Group’s supplemental new drug application for leniolisib in treating activated phosphoinositide ...
Leiden, the Netherlands, October 20, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that 12 abstracts have been accepted for presentation at ...
The new funds will allow the company to test its multi-node PI3K treatment approach in a new endometrial cancer trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback